Abstract
Sixteen HIV-infected patients with protease inhibitor (PI)-related, persisting hypercholesterolaemia were treated with 10 mg a day rosuvastatin for 24 weeks. At the end of the observation period, the median reductions in total cholesterol and triglyceride levels versus median baseline values were 21.7 and 30.1%, respectively (P < 0.01). In our small pilot study, rosuvastatin was found to be effective for the treatment of PI-associated hyperlipidaemia, in association with a favourable tolerability profile, without significant clinical or laboratory adverse events.
MeSH terms
-
Adult
-
Antiretroviral Therapy, Highly Active
-
Cholesterol / blood
-
Female
-
Fluorobenzenes / therapeutic use*
-
HIV Infections / drug therapy*
-
HIV Protease Inhibitors / adverse effects*
-
Humans
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
-
Hyperlipidemias / chemically induced
-
Hyperlipidemias / drug therapy*
-
Male
-
Middle Aged
-
Pilot Projects
-
Prospective Studies
-
Pyrimidines / therapeutic use*
-
Reverse Transcriptase Inhibitors / adverse effects*
-
Rosuvastatin Calcium
-
Sulfonamides / therapeutic use*
-
Triglycerides / blood
Substances
-
Fluorobenzenes
-
HIV Protease Inhibitors
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors
-
Pyrimidines
-
Reverse Transcriptase Inhibitors
-
Sulfonamides
-
Triglycerides
-
Rosuvastatin Calcium
-
Cholesterol